



ALERT

Pyrophosphate Shortage Reported, Expected to Persist in Coming Weeks

ASNC has received reports of shortages of the imaging agent ^{99m}Techetium-pyrophosphate (PYP) from two manufacturers. Both **Curium** and **Sun Radiopharma** have reported disruptions in their supply lines.

Curium informed ASNC it is out of PYP stock and is working to establish a return-to-stock date. Curium also shared that the supplier of the raw material used in the formulation of PYP has discontinued the product and Curium is working to find an alternate supplier so that production may resume as soon as possible.

Sun Radiopharma estimates a return to production in January 2024. The Sun Radiopharma notice is posted [here](#).

HMDP for Diagnosing Transthyretin Cardiac Amyloidosis

As a reminder, ASNC leadership reached a consensus clinical recommendation that ^{99m}Techetium-hydroxymethylene diphosphonate (HMDP; also sometimes abbreviated HDP; also referred to as ^{99m}Techetium oxidronate) can be used as an alternative to PYP for the diagnosis of transthyretin cardiac amyloidosis.

More information is available on the use of HMDP in the [ASNC and EANM Cardiac Amyloidosis Practice Points: ^{99m}Techetium-3,3-diphosphono-1,2-propanodicarboxylic acid \(DPD\) and ^{99m}Techetium-hydroxymethylene diphosphonate \(HMDP\) Imaging for Transthyretin Cardiac Amyloidosis](#).

Please contact your local pharmacy for the most up-to-date information regarding supply in your location. ASNC will report any updates from manufacturers as soon as possible. Contact us anytime at info@ASNC.org.

Working for you,
Your ASNC Team

P.S. - [Renew your membership today](#) to ensure you continue receiving important news alerts like this one.

ASNC | 9302 LEE HWY., STE. 1210 | FAIRFAX, VA | 22031
INFO@ASNC.ORG | 703-459-2555

Share this email:



[Manage](#) your preferences | [Opt out](#) using TrueRemove™

Got this as a forward? [Sign up](#) to receive our future emails.

View this email [online](#).

9302 Lee Highway Suite 1210
Fairfax, VA | 22031 US

This email was sent to .

To continue receiving our emails, add us to your address book.

[Subscribe](#) to our email list.